<http://webisa.webdatacommons.org/305009697>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/305009697>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<researchandmarkets.com> .
<http://webisa.webdatacommons.org/prov/144025000>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/305009697> .
<http://webisa.webdatacommons.org/305009697>	<http://www.w3.org/ns/prov#value>	"The development was a result of the new regulatory status of melatonin in Finland following a decision by The Finnish Medicine Agency (FIMEA) in November 2013, stating that products containing 0.5-1 mg of melatonin can be sold as dietary supplements and marketed with the European Commission approved health claims.The Calming and Sleeping in Finland report offers a comprehensive guide to the size a" .